Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

OBJECTIVE: The purpose of this study was to explore the efficacy and safety of transarterial chemoembolization (TACE) combined with apatinib and camrelizumab (TACE + AC) for unresectable hepatocellular carcinoma (HCC), and the impact of the timing of the combination on it. METHODS: In this single-ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Shuguang, Zhou, Chen, Hu, Junwen, Wang, Yingliang, Wang, Chaoyang, Liu, Jiacheng, Yang, Chongtu, Huang, Songjiang, Li, Tongqiang, Chen, Yang, Bai, Yaowei, Yao, Wei, Xiong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961945/
https://www.ncbi.nlm.nih.gov/pubmed/35346114
http://dx.doi.org/10.1186/s12885-022-09451-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961945/
https://www.ncbi.nlm.nih.gov/pubmed/35346114
http://dx.doi.org/10.1186/s12885-022-09451-1

Ejemplares similares